JOGC

Un mot à propos des hormones « bio-identiques »

      Après la publication des résultats de l'essai clinique de la Women's Health Initiative (WHI) sur l'association d'œstrogènes et de progestatifs,
      • Rossouw J.E.
      • Anderson G.L.
      • Prentice R.L.
      • LaCroix A.Z.
      • Kooperberg C.
      • Stefanick M.L.
      • et al.
      Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators.
      l'opinion publique s'est braquée contre l'utilisation de cette combinaison pharmaceutique chez les femmes postménopausées. Les protagonistes qui étaient en faveur de l'usage des préparations combinées d'œstrogènes et de progestérones (et qui en souhaitaient la commercialisation) ont profité du vide thérapeutique. C'était la chance qui n'arrivait qu'une fois dans la vie. Les partisans de l'usage de ces préparations ont inventé l'expression « bio-identique » pour en faire la promotion. Ils ont ainsi réussi un coup de maître sur le plan du marketing, car l'expression semblait à fois scientifique et naturelle.
      To read this article in full you will need to make a payment

      Références

        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • Kooperberg C.
        • Stefanick M.L.
        • et al.
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators.
        JAMA. 2002; 288: 321-333
        • Somers S.
        Ageless: The naked truth about bioidentical hormones.
        Crown Archetype, New York2006
        • Boothby L.A.
        • Doering P.L.
        • Kipersztok S.
        Bioidentical hormone therapy: a review.
        Menopause. 2004; 11: 356-367
        • Sood R.
        • Warndahl R.A.
        • Schroeder D.R.
        • Singh R.J.
        • Rhodes D.J.
        • Wahner-Roedler D.
        • et al.
        Bioidentical compounded hormones: a pharmacokinetic evaluation in a randomized clinical trial.
        Maturitas. 2013; 74: 375-382
        • Wren B.G.
        • McFarland K.
        • Edwards L.
        Micronised transdermal progesterone and endometrial response.
        Lancet. 1999; 354: 1447-1448
        • Benster B.
        • Carey A.
        • Wadsworth F.
        • Vashisht A.
        • Domoney C.
        • Studd J.
        A double-blind placebo-controlled study to evaluate the effect of progestelle progesterone cream on postmenopausal women.
        Menopause Int. 2009; 15: 63-69
        • Ruiz A.D.
        • Daniels K.R.
        • Barner J.C.
        • Carson J.J.
        • Frei C.R.
        Effectiveness of compounded bioidentical hormone replacement therapy: an observational cohort study.
        BMC Women's Health. 2011; 11: 27-37
        • Stephenson K.
        • Neuenschwander P.F.
        • Kurdowska A.K.
        The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
        Int J Pharm Compd. 2013; 17: 74-85
        • MacLennan A.H.
        • Broadbent J.L.
        • Lester S.
        • Moore V.
        Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes (review).
        Cochrane Database Syst Rev. 2004; : CD002978
        • Whelan A.M.
        • Jurgens T.M.
        • Trinacty M.
        Bioidentical progesterone cream for menopause-related vasomotor symptoms: is it effective?.
        Ann Pharmacother. 2013; 47: 112-116
        • American College of Obstetricians and Gynecologists Committee on Gynecologic Practice and American Society for Reproductive Medicine Practice Committee
        Compounded bioidentical menopausal hormone therapy.
        Fertil Steril. 2012; 98: 308-312

      Linked Article

      • A Word About Bioidenticals
        Journal of Obstetrics and Gynaecology Canada Vol. 38Issue 8
        • In Brief
          After publication of the findings in the Women's Health Initiative (WHI) combined estrogen-progestin trial,1 the public mood turned against the use of this pharmaceutical combination in postmenopausal women. Into the therapeutic void that followed leapt the protagonists who supported (and wished to market) compounded preparations of estrogens and progesterone. It was a once-in-a-generation opportunity. To assist in promoting the use of these preparations, their supporters coined the term “bioidentical.” It was a stroke of marketing genius because the word sounded both scientific and natural.
        • Full-Text
        • PDF